APP Pharmaceuticals, Teva Sign Gemcitabine HCI Agreement

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced Wednesday that it has entered into a commercialization, manufacture and supply agreement with Teva Pharmaceutical USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., to manufacture and market Gemcitabine HCI for Injection.
Seeking Alpha